Investigating how a specific chemokine can enhance immune responses to treat head and neck cancer.
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
This study is looking at how a substance called CXCL14 can help slow down the growth of head and neck cancers linked to HPV by boosting the immune system's ability to fight these tumors, with the goal of creating new treatments that can better target and destroy these cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10823265 on NIH RePORTER |
What this research studies
This research focuses on understanding how the chemokine CXCL14 can suppress the growth of head and neck cancers associated with human papillomavirus (HPV). The study aims to explore the mechanisms by which CXCL14 enhances the presentation of tumor antigens and activates immune responses, particularly CD8+ T cells, which are crucial for fighting cancer. By restoring CXCL14 levels in cancer cells, the researchers hope to develop new immunotherapies that can effectively target and eliminate HPV-positive tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HPV-positive head and neck squamous cell carcinoma.
Not a fit: Patients with HPV-negative head and neck cancers or those with other unrelated malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative immunotherapies that significantly improve treatment outcomes for patients with HPV-related head and neck cancers.
How similar studies have performed: Previous research has shown promising results with similar immunotherapeutic approaches targeting immune responses in cancer treatment.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Pyeon, Dohun — Michigan State University
- Study coordinator: Pyeon, Dohun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.